Clinical Investigation| Volume 355, ISSUE 5, P449-455, May 2018

Positive Correlation of Fecal Calprotectin With Serum Antioxidant Enzymes in Patients With Inflammatory Bowel Disease: Accidental Numerical Correlation or a New Finding?



      Oxidative stress occuring in patients diagnosed with inflammatory bowel disease (IBD), but the relationship between oxidative stress, disease activity and inflammatory markers has not been well established.

      Materials and Methods

      A total of 30 patients diagnosed with IBD and 30 volunteers who had normal colonoscopies, selected as controls, were used for this study. The serum levels of antioxidant enzymes (catalase and glutathione peroxidase) and oxidative markers (malondialdehyde [MDA] and total antioxidant capacity) were compared between the 2 groups. Furthermore, their correlations with disease activity scores and inflammatory markers, especially the fecal calprotectin, were examined.


      Catalase and glutathione peroxidase concentrations were significantly correlated with the level of fecal calprotectin in patients with IBD. Nevertheless, there were no significant correlations between the concentrations of the above-mentioned enzymes and C-reactive protein, erythrocyte sedimentation rate or the activity scores of IBD patients. It should be noted that MDA and total antioxidant capacity levels did not correlate with the inflammatory markers or the disease activity scores.


      There was a positive correlation between fecal calprotectin and serum antioxidant enzymes in patients with IBD, but, there was no correlation between antioxidant and oxidative markers in terms of disease activity scores. Hence, the observed significant correlation between the antioxidant enzymes and the fecal calprotectin may be due to either the pro-oxidant potential of calprotectin or its antioxidant role.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Abraham C.
        • Cho J.H.
        Inflammatory bowel disease.
        N Engl J Med. 2009; 361: 2066-2078
        • Achitei D.
        • Ciobica A.
        • Balan G.
        • et al.
        Different profile of peripheral antioxidant enzymes and lipid peroxidation in active and non-active inflammatory bowel disease patients.
        Dig Dis Sci. 2013; 58: 1244-1249
        • Schoepfer A.M.
        • Beglinger C.
        • Straumann A.
        • et al.
        Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes.
        Inflamm Bowel Dis. 2013; 19: 332-341
        • Van Assche G.
        Fecal biomarkers for the diagnosis and management of inflammatory bowel disease.
        Gastroenterol Hepatol (N Y). 2011; 7: 396
        • Costa F.
        • Mumolo M.
        • Ceccarelli L.
        • et al.
        Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease.
        Gut. 2005; 54: 364-368
        • Moein S.
        • Qujeq D.
        • Vaghari Tabari M.
        • et al.
        Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: from laboratory to clinic.
        Caspian J Intern Med. 2017; 8: 178-182
        • Dhas D.B.B.
        • Bhat B.V.
        • Gane D.B.
        Role of calprotectin in infection and inflammation.
        Curr Pediatr Res. 2012; 16: 83-94
        • Nolan J.D.
        • Johnston I.M.
        • Pattni S.S.
        • et al.
        Diarrhea in Crohn’s disease: investigating the role of the ileal hormone fibroblast growth factor 19.
        J Crohns Colitis. 2015; 9: 125-131
        • Miklavcic J.J.
        • Hart T.D.
        • Lees G.M.
        • et al.
        Increased catabolism and decreased unsaturation of ganglioside in patients with inflammatory bowel disease.
        World J Gastroenterol. 2015; 21: 10080-10090
        • Mohammadi E.
        • Qujeq D.
        • Taheri H.
        • et al.
        Evaluation of serum trace element levels and superoxide dismutase activity in patients with inflammatory bowel disease: translating basic research into clinical application.
        Biol Trace Elem Res. 2017; 177: 235-240
        • Tuzun A.
        • Erdil A.
        • Inal V.
        • et al.
        Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease.
        Clin Biochem. 2002; 35: 569-572
        • Vaghari Tabari M.
        • Moein S.
        • Qujeq D.
        • et al.
        Examination of the potential antioxidant role of high-density lipoprotein-cholesterol (HDL-C) in patients with ulcerative colitis.
        Ann Colorectal Res. 2017; : e13699
        • Piechota-Polanczyk A.
        • Fichna J.
        Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.
        Naunyn Schmiedebergs Arch Pharmacol. 2014; 387: 605-620
        • Esworthy R.S.
        • Aranda R.
        • Martin M.G.
        • et al.
        Mice with combined disruption of Gpx1 and Gpx2 genes have colitis.
        A Am J Physiol Gastrointest Liver Physiol. 2001; 281: G848-G855
        • Kim H.-R.
        • Lee A.
        • Choi E.-J.
        • et al.
        Attenuation of experimental colitis in glutathione peroxidase 1 and catalase double knockout mice through enhancing regulatory T cell function.
        PLoS One. 2014; 9: e95332
        • Moura F.A.
        • de Andrade K.Q.
        • dos Santos J.C.F.
        • et al.
        Antioxidant therapy for treatment of inflammatory bowel disease: does it work?.
        Redox Biol. 2015; 6: 617-639
        • Boyum A.
        • Skrede K.K.
        • Myhre O.
        • et al.
        Calprotectin (S100A8/S100A9) and myeloperoxidase: co-regulators of formation of reactive oxygen species.
        Toxins. 2010; 2: 95-115
        • Best W.R.
        • Becktel J.M.
        • Singleton J.W.
        • et al.
        Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study.
        Gastroenterology. 1976; 70: 439-444
        • Lichtiger S.
        • Present D.H.
        • Kornbluth A.
        • et al.
        Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
        N Engl J Med. 1994; 330: 1841-1845
        • Mosli M.H.
        • Feagan B.G.
        • Zou G.
        • et al.
        Development and validation of a histological index for UC.
        Gut. 2015;
        • Walsh A.J.
        • Bryant R.V.
        • Travis S.P.
        Current best practice for disease activity assessment in IBD.
        Nat Rev Gastroenterol Hepatol. 2016; 13: 567-579
        • Benzie I.F.
        • Strain J.
        The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power: the FRAP assay.
        Anal Biochem. 1996; 239: 70-76
        • Ohkawa H.
        • Ohishi N.
        • Yagi K.
        Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction.
        Anal Biochem. 1979; 95: 351-358
        • Qujeq D.
        • Aliakbarpour H.R.
        • Kalavi K.
        Relationship between malondialdehyde level and glutathione peroxidase activity in diabetic rats.
        Clinica Chimica Acta. 2004; 340: 79-83